ArticleBMC gastroenterology2026
Nonlinear associations of remnant cholesterol/high-density lipoprotein cholesterol ratio with the risk of metabolic-associated fatty liver disease: a cross-sectional study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to explore the association between the ratio of remnant cholesterol to high-density lipoprotein cholesterol (RC/HDL-C) and metabolic-associated fatty liver disease (MAFLD).
methodsThis cross-sectional study included 2,589 participants underwent physical examinations from 2015 to 2017. Logistic regression, restricted cubic spline (RCS), subgroup analysis and receiver operating characteristic (ROC) curve analysis were applied to assess the association between RC/HDL-C ratio and the risk of MAFLD.
resultsThere is a positive correlation between RC/HDL-C ratio and the risk of MAFLD (P for trend < 0.001). Results from the multivariate logistic regression analysis showed a positive association between RC/HDL-C ratio and MAFLD (Q4 vs. Q1: OR = 5.91, 95%CI: 4.06–8.74). The results remain stable in subgroup analyses. RCS analysis showed a significant non-linear dose-response relationship (P for nonlinear < 0.001) between RC/HDL-C ratio and the risk of MAFLD. ROC analysis indicated that RC/HDL-C had modest discriminative ability for MAFLD (AUC = 0.778, 95%CI: 0.758–0.797).
conclusionsThis cross-sectional study found a significant nonlinear positive relationship between RC/HDL-C and MAFLD, and RC/HDL-C showed modest discriminative ability for MAFLD. These findings suggest that RC/HDL-C may serve as a potential risk-related biomarker for MAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.